Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in XXXX prostate in different @entity342 status.

@entity1 @entity251 @entity263 @entity586 @entity1067 @entity134 @entity342 @entity4623 @entity35 @entity587 @entity3800
BACKGROUND: The incidence of @entity263 ( @entity263 ) and @entity1067 ( @entity1067 ) continues to rise in the Western world. The development and growth of the prostate gland depends on @entity342 stimulation. @entity586 ( @entity587 ) is the primary @entity342 responsible for prostate development and also for the pathogenesis of @entity1067 ( @entity1067 ). @entity587 is synthesized in prostate from circulating @entity251 (T) through the action of 5alpha-Reductase (5alpha-R) (EC 1.3.99.5), which occurs as two isozymes, type-1 and type-2. Both types are expressed in the prostate: type-2 isozyme is predominantly expressed in prostate and is implicated in @entity1067 and @entity263 ; type-1 isozyme is also increased in some @entity263 . In recent years, various inhibitors of type-2 isozyme or of both type-1 and type-2 isozyme have been used in @entity4623 . METHODS: We present the first published measurements of mRNA levels of @entity134 5alpha-R isozymes in the ventral prostate of @entity35 of different @entity342 status. We used a novel method that combines the high specificity of competitive PCR with the sensitivity of laser-induced capillary electrophoresis (LIF-CE). RESULTS: We demonstrated that T and @entity587 @entity3800 control the expression of both 5alpha-R isozymes in @entity35 prostrate. CONCLUSIONS: This approach could be of great value for the study of @entity4623 in @entity1 and would allow study at the transcriptional level of the effects of drugs that inhibit either or both of these isozymes.
